U.S. markets closed
  • S&P 500

    3,666.72
    -2.29 (-0.06%)
     
  • Dow 30

    29,969.52
    +85.73 (+0.29%)
     
  • Nasdaq

    12,377.18
    +27.82 (+0.23%)
     
  • Russell 2000

    1,848.70
    +10.67 (+0.58%)
     
  • Crude Oil

    45.64
    +0.36 (+0.80%)
     
  • Gold

    1,844.80
    +14.60 (+0.80%)
     
  • Silver

    24.19
    +0.11 (+0.46%)
     
  • EUR/USD

    1.2148
    +0.0032 (+0.27%)
     
  • 10-Yr Bond

    0.9200
    -0.0280 (-2.95%)
     
  • GBP/USD

    1.3454
    +0.0079 (+0.59%)
     
  • USD/JPY

    103.8500
    -0.5740 (-0.55%)
     
  • BTC-USD

    19,451.80
    +502.90 (+2.65%)
     
  • CMC Crypto 200

    382.32
    +7.92 (+2.11%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

Summit Therapeutics Inc (SMMT) CEO Robert W Duggan Bought $47 million of Shares

GuruFocus.com
·1 min read

- By insider

CEO of Summit Therapeutics Inc (30-Year Financial, Insider Trades) Robert W Duggan (insider trades) bought 14,071,856 shares of SMMT on 11/06/2020 at an average price of $3.34 a share. The total cost of this purchase was $47 million.


Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit Therapeutics Inc has a market cap of $1.14 billion; its shares were traded at around $3.38 with and P/S ratio of 35.96. GuruFocus has detected 5 severe warning signs with Summit Therapeutics Inc. .

CEO Recent Trades:

  • CEO, 10% Owner Robert W Duggan bought 14,071,856 shares of SMMT stock on 11/06/2020 at the average price of $3.34. The price of the stock has increased by 1.2% since.

For the complete insider trading history of SMMT, click here

.This article first appeared on GuruFocus.